Note
16 - Earnings Per Share
Basic
earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average
number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other
contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that
shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of
shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.
ProPhase
Labs, Inc. and Subsidiaries
Notes
to Condensed Consolidated Financial Statements
(unaudited)
The
following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss
per share (in thousands):
Schedule of Basic and Diluted Net Loss Per Share
|
|
March 31, 2022 |
|
|
March 31, 2021 |
|
|
|
For the three months ended |
|
|
|
March 31, 2022 |
|
|
March 31, 2021 |
|
Net income - basic |
|
$ |
12,494 |
|
|
$ |
1,057 |
|
Interest on unsecured convertible promissory note |
|
|
232 |
|
|
|
- |
|
Net income - diluted |
|
$ |
12,726 |
|
|
$ |
1,057 |
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding - basic |
|
|
15,486 |
|
|
|
14,563 |
|
Diluted shares- Stock Options |
|
|
2,232 |
|
|
|
2,895 |
|
Diluted shares- Stock Warrants |
|
|
222 |
|
|
|
284 |
|
Unsecured convertible promissory note |
|
|
800 |
|
|
|
458 |
|
Weighted average shares outstanding - diluted |
|
|
18,740 |
|
|
|
18,200 |
|
The
following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive
effect (in thousands):
Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation
|
|
For the three months ended |
|
Anti-dilutive securities |
|
March 31, 2022 |
|
|
March 31, 2021 |
|
Common stock purchase warrants |
|
|
455 |
|
|
|
455 |
|
Stock Options |
|
|
810 |
|
|
|
- |
|
Anti-dilutive securities |
|
|
1,265 |
|
|
|
455 |
|
|